

Microviable Therapeutics Appoints Luis Gosálbez as a member of its Business Advisory Board

Gijón, March 13th 2023. Microviable Therapeutics SL a biotech company at preclinical stage developing novel microbiome-derived biotherapeutic products, today announced the appointment of Dr. Luis Gosálbez as a member of its Business Advisory Board. Gosálbez brings 10 years of experience in business strategy and corporate development for life sciences companies specialized in microbiome and probiotics industry, with additional extensive experience in regulatory affairs.

“Luis’ experience overseeing business strategy, market access and regulatory intelligence in previous biotech organizations, with strong expertise on microbiome industry, provides him a unique and broad perspective of this emerging field where microbiome-derived products are being developed as novel biological drugs”, said Claudio Hidalgo, Ph.D., co-founder and Chief Executive Officer of Microviable Therapeutics. *“We are excited to welcome Luis Gosálbez on board as strategic advisor and look forward to his contributions.”*

Luis Gosálbez held different roles as business development, innovation and strategy executive at Clasado Biosciences, OptiBiotix Health and Biopolis, establishing corporate alliances, business strategy and commercial launch. Since 2018 he is the co-founder and Managing Director of Sandwalk Bioventures, an end-to-end innovation, strategy, regulatory intelligence and management consulting firm specialized in microbiome technologies. Gosálbez earned his MBA in from the University of Cambridge, his PhD in Life Sciences from UCAM, his M.Sc. in Biotechnology and B.Sc. in Biology from Universidad Complutense de Madrid.

“Microviable has strength its development platform for complete microbiota ecosystem products and bacterial consortia, and I am thrilled to join at this growth stage contributing to stablish its leadership position on the microbiome industry and advance their lead candidate into clinical trials”, said Luis Gosálbez.

About Microviable Therapeutics SL

[Microviable Therapeutics](#) is a preclinical stage biotechnology company developing orally administered biological drugs based on microbiota-derived biotherapeutic products. The company’s strong expertise on anaerobic bacteria provided a unique position to develop complete microbiota ecosystem products and defined bacterial consortia, to address unmet challenges in various human diseases. Microviable has built a proprietary, large

and diverse bacterial strain culture collection derived from the human microbiome together with extensive metagenomic data set. The lead candidate MVT-201, for undisclosed infectious disease will enter clinical trials in Q4 2023 and the company held another four preclinical programs ongoing in dermatology and oncology. Microviable was founded in 2016 as a spinoff company from the Spanish National Research Council (CSIC) with a leading scientific team pioneering the microbiome research. Microviable has developed commercial products like the medical device for microbiome sampling [GutAlive®](#) and provided ad-hoc services and end-to-end projects for biotech, food and pharma companies. Microviable received significant funding from the private medical group [Inmunomet Intolerancias y Disbiosis](#) in 2022 to advance its microbiome-based drug development platform into the clinic.